[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632897":3},{"organization":4,"armGroups":7,"interventions":48,"overallOfficials":55,"centralContacts":59,"locations":64,"responsibleParty":116,"collaborators":54,"id":118,"slug":119,"hasResults":120,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":54,"eligibilityCriteria":124,"healthyVolunteers":120,"sex":125,"minAge":126,"maxAge":54,"enrollmentInfo":127,"targetDuration":54,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":138,"overallStatus":67,"whyStopped":54,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,14,18,22,26,30,34,38,42,45],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Cohort 1","EXPERIMENTAL","Participants will receive PF-08046033 dose level 1 intravenously (IV).",[13],"Drug: PF-08046033",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 1: Cohort 2","Participants will receive PF-08046033 dose level 2 IV.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Part 1: Cohort 3","Participants will receive PF-08046033 dose level 3 IV.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Part 1: Cohort 4","Participants will receive PF-08046033 dose level 4 IV.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Part 1: Cohort 5","Participants will receive PF-08046033 dose level 5 IV.",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Part 1: Cohort 6","Participants will receive PF-08046033 dose level 6 IV.",[13],{"label":35,"type":10,"description":36,"interventionNames":37},"Part 1: Cohort 7","Participants will receive PF-08046033 dose level 7 IV.",[13],{"label":39,"type":10,"description":40,"interventionNames":41},"Part 2: Cohort 1 Non-Small Cell Lung Cancer (NSCLC)","PF-08046033: Specified dose IV on specified days",[13],{"label":43,"type":10,"description":40,"interventionNames":44},"Part 2: Cohort 2 Esophageal Squamous Cell Carcinoma (ESCC)",[13],{"label":46,"type":10,"description":40,"interventionNames":47},"Part 2: Cohort 3 (Cutaneous Melanoma)",[13],[49],{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"DRUG","PF-08046033","Powder for solution for infusion.",[9,15,19,23,27,31,35,39,43,46],null,[56],{"name":57,"affiliation":5,"role":58},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[60],{"name":57,"role":61,"phone":62,"phoneExt":54,"email":63},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[65,79,84,95,100,111],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":54},"Presbyterian\u002FSt Lukes Medical Center","RECRUITING","Denver","Colorado","80218","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-104.9847,39.73915,{"lat":77,"lon":76},{"facility":80,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":81,"geoPoint":83,"contacts":54},"Sarah Cannon Research Institute at HealthONE",{"type":74,"coordinates":82},[76,77],{"lat":77,"lon":76},{"facility":85,"status":86,"city":87,"state":88,"zip":89,"country":71,"countryCode":72,"cosmosGeoPoint":90,"geoPoint":94,"contacts":54},"Sarah Cannon Research Institute- Pharmacy","NOT_YET_RECRUITING","Nashville","Tennessee","37203",{"type":74,"coordinates":91},[92,93],-86.78444,36.16589,{"lat":93,"lon":92},{"facility":96,"status":86,"city":87,"state":88,"zip":89,"country":71,"countryCode":72,"cosmosGeoPoint":97,"geoPoint":99,"contacts":54},"SCRI Oncology Partners",{"type":74,"coordinates":98},[92,93],{"lat":93,"lon":92},{"facility":101,"status":67,"city":102,"state":54,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":110,"contacts":54},"Hospital Oncologico Dr. Isaac Gonzalez-Martinez","Rio Piedras","00935","Puerto Rico","PR",{"type":74,"coordinates":107},[108,109],-66.04989,18.39745,{"lat":109,"lon":108},{"facility":112,"status":67,"city":102,"state":54,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":113,"geoPoint":115,"contacts":54},"Pan American Center for Oncology Trials, LLC",{"type":74,"coordinates":114},[108,109],{"lat":109,"lon":108},{"type":117,"investigatorFullName":54,"investigatorTitle":54,"investigatorAffiliation":54,"oldNameTitle":54,"oldOrganization":54},"SPONSOR","100632897","phase-1-phase-1-study-of-pf-08046033-in-advanced-solid-tumors-100632897",false,"NCT07519655","Phase 1 Study of PF-08046033 in Advanced Solid Tumors","A Phase 1 Study to Investigate PF-08046033 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Participants must have histologically-confirmed metastatic or unresectable locally advanced NSCLC, ESCC, or cutaneous melanoma.\n2. Participants must have disease that has progressed on or be unable to tolerate standard treatments (Part 1) or 1-2 prior systemic therapies (Part 2).\n3. Participants must have measurable disease.\n4. Eastern Cooperative Oncology Group (ECOG) performance status is 0-1.\n\nExclusion Criteria:\n\n1. Participants with known clinically active central nervous system (CNS) metastases.\n2. Participants with pre-existing neuropathy ≥Grade 2 per NCI CTCAE v 5.0.\n3. Uncontrolled diabetes mellitus with hemoglobin (Hgb) A1C ≥10.0%.\n4. Untreated clinically significant thromboembolic disease.\n5. Previous exposure to GPNMB-targeted therapy.\n6. Known or suspected hypersensitivity to any component or excipient contained in the drug formulation of study intervention.","ALL","18 Years",{"count":128,"type":129},250,"ESTIMATED","INTERVENTIONAL",[132],"PHASE1","This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer.\n\nThe study includes adult participants who have advanced cancers that cannot be removed by surgery or have spread to other parts of the body. These cancers include non-small cell lung cancer, esophageal squamous cell cancer, and melanoma.\n\nThe study has two parts:\n\nIn the first part, small groups of participants receive increasing doses of the study medicine. This helps researchers find a dose that is safe and suitable for further testing.\n\nOnce a suitable dose is identified, the second part enrolls more participants with specific cancer types to better understand the safety of the medicine and whether it shows signs of helping control the cancer.\n\nParticipants receive the study medicine through regular treatment cycles and are closely monitored for side effects and how their cancer responds. The information from this study will help researchers decide whether PF-08046033 should be studied further in later-stage clinical trials.",[135,136,137],"Non-Small-Cell Lung","Esophageal Cancer","Cutaneous Melanoma",[139,140,141,142],"Lung cancer","Esophageal cancer","Melanoma","Antibody drug conjugate","2026-04-20",{"date":145,"type":146},"2026-04-23","ACTUAL",{"date":148,"type":146},"2026-04-08",{"date":150,"type":129},"2029-07-14",{"name":5,"class":6},6]